8-K Announcements
6Material company update
Apr 22, 2026·SEC
Material company update
Mar 19, 2026·SEC
Material company update
Jan 13, 2026·SEC
Aclarion, Inc.(ACON)Earnings, Financials & Key Ratios
ACON•NASDAQ
$2.99
Price updated Jul 7, 2026
AboutAclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.Show more
- Revenue$76K+65.6%
- EBITDA-$7M-28.3%
- Net Income-$7M-3.4%
- EPS (Diluted)-13.61+99.8%
- Gross Margin-291.27%-58.5%
- EBITDA Margin-9012.26%+22.5%
- Operating Margin-9312.55%+22.8%
- Net Margin-9551.87%+37.5%
- ROE-104.8%+98.2%
ACON Price & Volume
Aclarion, Inc. (ACON) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Volatility Masks Deep Operational Deficits
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Capital structure and liquidity
Key Thesis Takeaways
- Aclarion faces a challenging path to commercial viability as its diagnostic software suite struggles to achieve meaningful scale, with quarterly revenue hovering near $21.1K as of 2026Q1.
- The company remains heavily reliant on external capital to fund its $315.4K quarterly R&D spend, leading to a cumulative retained earnings deficit of $61.3 million.
- Investors should remain cautious given the lack of a repeatable sales motion and the ongoing necessity for dilutive financing to sustain operations.
Verdict Logic
the company exhibits a precarious financial profile characterized by a 141.3% negative operating margin and a persistent inability to generate positive free cash flow, which necessitates ongoing reliance on dilutive capital raises.
ACON Growth Metrics
Aclarion, Inc. (ACON) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years9.25%
3 Years7.8%
TTM42.63%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-21.39%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM99.78%
Return on Capital
10 Years-1389.53%
5 Years-1389.53%
3 Years-1769.42%
Last Year-102.17%
ACON Recent Earnings
Aclarion, Inc. (ACON) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (18%)
Q2 2026Latest
May 21, 2026Metric
Actual
Est
EPS
$1.34+13.5%
$1.55
Rev
$21,140-15.4%
$25,000
Q2 2026
May 13, 2026Metric
Actual
Est
EPS
$1.34+13.5%
$1.55
Rev
$21,140-15.4%
$25,000
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$3.60+0.0%
$3.60
Rev
$20,000+0.0%
$20,000
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$2.93-11.0%
$2.64
Rev
$18,942-0.3%
$19,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 21, 2026 | $1.34vs $1.55+13.5% | $21,140vs $25,000-15.4% |
| Q2 2026 | May 13, 2026 | $1.34vs $1.55+13.5% | $21,140vs $25,000-15.4% |
| Q1 2026 | Feb 25, 2026 | $3.60vs $3.60+0.0% | $20,000vs $20,000+0.0% |
| Q4 2025 | Nov 12, 2025 | $2.93vs $2.64-11.0% | $18,942vs $19,000-0.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Aclarion, Inc. (ACON)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.99 | $1.59M | -0.22 | 65.62% | -9551.87% | -104.8% | — | |
| $0.42 | $58.84M | 13.98 | 14.21% | 1.5% | 3.68% | — | |
| $150.65 | $8.82B | -45.93 | 32.33% | -34.34% | -26.46% | — | |
| $4.20 | $623.98M | 13.13 | 19.99% | 7.88% | 12.86% | — | |
| $9.38 | $1.42B | -9.77 | 24.95% | -21.07% | -443.09% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — |
Compare ACON vs Peers
Aclarion, Inc. (ACON) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ACON SEC Filings & Documents
Aclarion, Inc. (ACON) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ACON posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ACON Frequently Asked Questions
Aclarion, Inc. (ACON) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Aclarion, Inc.'s revenue?
Aclarion, Inc. (ACON) reported $0.1M in revenue for fiscal year 2025. This represents a 190% increase from $0.0M in 2019.
How fast is Aclarion, Inc. growing?
Aclarion, Inc. (ACON) grew revenue by 65.6% over the past year. This is strong growth.
Is ACON profitable?
Aclarion, Inc. (ACON) reported a net loss of $8.0M for fiscal year 2025.
Dividend & Returns
What is ACON's return on equity?
Aclarion, Inc. (ACON) has a return on equity (ROE) of -104.8%. Negative ROE indicates the company is unprofitable.
What is Aclarion, Inc.'s free cash flow?
Aclarion, Inc. (ACON) had negative free cash flow of $7.3M in fiscal year 2025, likely due to heavy capital investments.